Default company panoramic image
Logo

effimune

Effimune is developping new immunomodulators in autoimmunity and transplantation to restore the immune system and to reduce side effects.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Nantes, Pays de la Loire, France
  • Currency EUR
  • Founded February 2007
  • Employees 8
  • Website effimune.com

Company Summary

Effimune is developing 3 monoclonal antibodies : FR104, EFfi7-h and MP196 which are selectively blocking effector T cells while enhancing regulatory T cells responses. The FR104, first in class has the potential to restore the immune tolerance which is deficient in patients suffering from some autoimmune diseases or after organ or cells transplantation.

Team

  • Default avatar
    Maryvonne Hiance
    Chairman

  • Default avatar
    Bernard Vanhove
    R&D Director

  • Default avatar
    Jean Paul Soulillou
    SAB Chairman

  • Default avatar
    Didier Coquoz
    Development & regulatory Affairs

Advisors

  • Default avatar
    HBC/ Cornet Vincent Ségurel
    Lawyer
    Unconfirmed
    Default avatar
    In Extenso Ouest Atlantique
    Accountant
    Unconfirmed